Type 2 Diabetes Mellitus — Comprehensive Management

• Insulin Resistance (Primary Defect): Insulin resistance represents the earliest detectable abnormality in T2DM pathogenesis and is present even in normoglycemic first-degree relatives of affected individuals. At the molecular level, insulin signaling is impaired through multiple mechanisms: (1) reduced insulin receptor substrate (IRS-1) expression or serine phosphorylation (which interferes with the phosphatidylinositol 3-kinase [PI3K] pathway), (2) decreased expression and translocation of GLUT4 glucose transporters in skeletal muscle and adipose tissue, and (3) impaired activation of protein kinase B (Akt), preventing glucose uptake. Obesity, particularly visceral adiposity, exacerbates insulin resistance through increased secretion of pro-inflammatory adipokines (TNF-α, IL-6), elevation of free fatty acids (FFAs), and paradoxical decreased adiponectin secretion. Ectopic fat deposition in muscle and liver further compromises insulin signaling. Glucose uptake in skeletal muscle and liver becomes impaired, while hepatic glucose production remains elevated, establishing a cycle of hyperglycemia. The HOMA-IR score (Homeostasis Model Assessment–Insulin Resistance), calculated as (fasting insulin × fasting glucose) / 405, quantifies degree of insulin resistance; values >2.5 suggest clinically significant resistance.

• Progressive β-Cell Dysfunction: Although insulin resistance is the initial driver, T2DM progresses because pancreatic β-cells cannot sustain adequate compensatory hyperinsulinemia. The natural history involves a decline in β-cell mass (through apoptosis) and function over 10–20 years. Multiple mechanisms contribute: (1) glucotoxicity—chronic hyperglycemia impairs glucose-stimulated insulin secretion (GSIS) through mitochondrial dysfunction and oxidative stress, (2) lipotoxicity—elevated FFAs and intracellular lipid metabolites (diacylglycerols, ceramides) inhibit insulin signaling and increase apoptosis, (3) amyloidosis—misfolding and aggregation of islet amyloid polypeptide (IAPP/amylin) within islet cells directly damages β-cells, (4) chronic inflammation and islet infiltration by T-cells and macrophages, and (5) impaired incretin axis function. The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) normally mediate 50–70% of postprandial insulin secretion; their secretion is reduced in T2DM, and their action is diminished. By the time overt hyperglycemia develops, approximately 50% of β-cell function has been lost.

• Defective Hepatic Glucose Homeostasis: The liver plays a critical role in T2DM pathophysiology. Hepatic insulin resistance leads to impaired suppression of hepatic glucose production (HGP) despite elevated insulin levels. This occurs through reduced activation of the FoxO1 transcription factor pathway (normally inhibited by insulin), allowing excessive expression of gluconeogenic enzymes (PEPCK, G6Pase) and the rate-limiting enzyme for glycogenolysis. Simultaneously, increased FFA delivery to hepatocytes promotes hepatic steatosis (nonalcoholic fatty liver disease [NAFLD]), which further worsens insulin resistance through mitochondrial inflammation and activation of JNK and IκB kinase pathways. Reduced hepatic glycogen synthesis capacity in some patients contributes to dysglycemia during fasting states.

• Altered Gut Hormones and Intestinal Dysfunction: Beyond the pancreas, T2DM involves dysregulation of enteroendocrine secretion. Reduced postprandial GLP-1 and GIP secretion, combined with reduced sensitivity of β-cells to these hormones, impairs glucose-stimulated insulin secretion. Additionally, hyperglucagonemia (inappropriately elevated glucagon in the fed state) paradoxically increases hepatic glucose output. Intestinal dysbiosis and altered microbiota composition contribute to increased intestinal permeability ("leaky gut"), endotoxemia, and systemic low-grade inflammation.

• Chronic Systemic Inflammation: T2DM is characterized by a state of chronic, low-grade inflammation (sometimes termed "metaflammation"). Elevated circulating C-reactive protein (CRP), TNF-α, and IL-6 levels reflect activation of toll-like receptor (TLR) pathways by FFAs and bacterial lipopolysaccharides. Adipose tissue macrophage infiltration shifts from the alternatively activated M2 phenotype (anti-inflammatory) to the classically activated M1 phenotype (pro-inflammatory). This inflammatory milieu directly impairs insulin signaling, promotes β-cell apoptosis, and accelerates atherosclerosis, explaining the tight link between T2DM and cardiovascular disease.

• Genetic and Epigenetic Factors: Twin studies demonstrate heritability of 50–70%. Over 400 genetic loci have been identified through genome-wide association studies (GWAS) that confer risk for T2DM, although individually each contributes small effect sizes. Key genes include those encoding TCF7L2 (transcription factor 7-like 2, affecting β-cell function), PPARG (peroxisome proliferator-activated receptor γ, a master regulator of adipogenesis and insulin sensitivity), and KCNJ11/ABCC8 (involved in ATP-sensitive potassium channels regulating insulin secretion). Epigenetic modifications (DNA methylation, histone acetylation) induced by environmental exposures (diet, physical inactivity, prenatal undernutrition) alter gene expression without changing DNA sequence, explaining the marked phenotypic heterogeneity and gene-environment interactions.

• Obesity and Metabolic Syndrome: Central/visceral obesity is the strongest modifiable risk factor for T2DM development. Approximately 85% of T2DM patients are overweight (BMI ≥25 kg/m²) or obese (BMI ≥30 kg/m²). The metabolic syndrome—a cluster of insulin resistance, abdominal obesity, dyslipidemia (elevated triglycerides, low HDL), and hypertension—markedly increases T2DM risk. Even modest weight loss (5–10% of body weight) significantly improves insulin sensitivity and glycemic control, highlighting the critical contribution of weight to disease pathogenesis.

• Physical Inactivity: Sedentary lifestyle is an independent risk factor. Regular aerobic and resistance exercise enhances GLUT4 translocation through insulin-independent mechanisms (involving AMP-activated protein kinase [AMPK] and calcium/calmodulin-dependent protein kinase II), improves β-cell function, and reduces cardiovascular risk. The Diabetes Prevention Program (DPP) study demonstrated that lifestyle intervention (moderate-intensity exercise ≥150 minutes weekly plus weight loss) reduced diabetes incidence by 58% in high-risk individuals.

• Dietary Factors: Consumption of refined carbohydrates, simple sugars, trans fats, and processed foods increases T2DM risk. Conversely, diets high in fiber, whole grains, legumes, nuts, and polyunsaturated fats reduce risk. Excessive sugar-sweetened beverage consumption is particularly strongly associated with T2DM incidence in prospective cohort studies.

• Age and Demographics: T2DM incidence and prevalence increase markedly with age, particularly after age 45. Non-Hispanic white individuals have the lowest prevalence; African Americans, Hispanic Americans, Native Americans, Asian Americans, and Pacific Islander Americans have 1.5–4-fold higher prevalence, reflecting both genetic susceptibility and socioeconomic factors affecting lifestyle and healthcare access.

• Impaired Glucose Tolerance and Prediabetes: Individuals with impaired fasting glucose (IFG: 100–125 mg/dL) or impaired glucose tolerance (IGT: 2-hour glucose 140–199 mg/dL on OGTT) are in a prediabetic state with annual diabetes progression rates of approximately 5–10%. The natural history shows that 25–30% of prediabetic individuals progress to overt T2DM over 3–5 years.

• Polycystic Ovary Syndrome (PCOS): Affects 6–10% of reproductive-age women and is associated with significant insulin resistance and a 30–40% lifetime risk of T2DM, independent of obesity.

• Gestational Diabetes Mellitus (GDM): Women with prior GDM have a 50% risk of developing T2DM within 10 years postpartum. GDM represents unmasking of underlying insulin resistance during the metabolic stresses of pregnancy.

• Secondary Causes of T2DM-Like Hyperglycemia: While not "true" T2DM, the following conditions cause similar hyperglycemia: (1) chronic pancreatitis or pancreatic surgery (loss of β-cell mass), (2) hemochromatosis (iron-mediated pancreatic damage), (3) Cushing's syndrome (glucocorticoid excess enhances hepatic glucose output and impairs peripheral glucose uptake), (4) acromegaly (growth hormone antagonizes insulin action), (5) pheochromocytoma (catecholamines increase hepatic glucose output), (6) thiazide diuretics and glucocorticoids (medications impairing β-cell function), and (7) hepatitis C (particularly genotype 1b).

• Family History of Diabetes: First-degree relatives of T2DM patients have 2–6-fold increased lifetime risk compared to the general population.

• Polyuria: Osmotic diuresis from glucosuria (when plasma glucose exceeds the renal threshold of ~180 mg/dL) causes excessive urinary water loss and frequent urination, particularly nocturia. Patients may awaken multiple times per night to urinate. The physiologic mechanism involves reduced aquaporin-2 expression in collecting duct cells in response to hyperglycemia, impairing water reabsorption.

• Polydipsia: Hyperglycemia increases serum osmolality, stimulating osmoreceptors in the hypothalamic thirst center. Additionally, polyuria-induced volume depletion activates the renin-angiotensin system and baroreceptor-mediated thirst. Patients report excessive thirst and increased fluid intake, particularly for sweet beverages.

• Fatigue and Malaise: Cellular energy depletion from impaired glucose uptake and utilization, coupled with elevated inflammatory cytokine levels, produces nonspecific fatigue, weakness, and reduced exercise tolerance. Patients often report difficulty with concentration and reduced work productivity.

• Weight Loss or Stable Weight: Unlike type 1 diabetes where rapid weight loss predominates, T2DM presentation often includes stable or increased weight due to ongoing insulin secretion. However, some patients (particularly in early presentations with severe hyperglycemia) report modest weight loss from glycosuria-induced osmotic losses.

• Recurrent Infections: Hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and complement activation, predisposing to bacterial and fungal infections. Women present with recurrent vulvovaginal candidiasis (Candida albicans thrives in glucose-rich urine and genital secretions). Men may present with balanitis. Both sexes are susceptible to recurrent urinary tract infections, skin infections (folliculitis, carbuncles), and oral candidiasis. Fungal superinfections of intertrigo in skinfolds are common.

• Visual Disturbances: Hyperglycemia causes osmotic changes in the lens (sorbitol accumulation through the aldose reductase pathway), leading to refractive errors and blurred vision. Chronic hyperglycemia causes diabetic retinopathy (nonproliferative initially, then proliferative), which may present with floaters, visual field loss, or sudden vision loss if macular edema or vitreous hemorrhage occurs.

• Paresthesias and Neuropathic Pain: Chronic hyperglycemia promotes distal symmetrical sensorimotor polyneuropathy (the most common form of diabetic neuropathy) through multiple mechanisms: (1) polyol pathway activation—excess glucose is shunted to sorbitol by aldose reductase, accumulating in nerve cells and causing osmotic stress; (2) advanced glycation end products (AGEs)—non-enzymatic glycation of myelin and axonal proteins impairs function; (3) oxidative stress from mitochondrial dysfunction and NAD(P)H depletion; (4) inflammation from TLR4 activation. Patients report burning pain, tingling, or numbness typically in a stocking-and-glove distribution, beginning distally in lower extremities. Autonomic neuropathy may present with erectile dysfunction (in 40–50% of men with T2DM), orthostatic hypotension, gastroparesis, or sudomotor dysfunction (abnormal sweating).

• Dyslipidemia-Related Symptoms: Accelerated atherosclerosis from chronic hyperglycemia and dyslipidemia may present with angina or dyspnea. Notably, T2DM patients often have silent myocardial ischemia (due to autonomic neuropathy and blunted pain perception), necessitating active screening.

• Fasting Plasma Glucose (FPG): FPG ≥126 mg/dL (≥7.0 mmol/L) on at least two separate occasions is diagnostic. Normal fasting glucose is <100 mg/dL; impaired fasting glucose (prediabetes) is 100–125 mg/dL. FPG has excellent specificity but lower sensitivity (~85%) because hyperglycemia may only be evident in the fed state. The fasting state is defined as ≥8 hours without caloric intake.

• 2-Hour Plasma Glucose on 75-g Oral Glucose Tolerance Test (OGTT): A 2-hour glucose ≥200 mg/dL (≥11.1 mmol/L) is diagnostic. The OGTT is most sensitive for detecting dysglycemia but is cumbersome, time-consuming, and less frequently used in routine practice. Values between 140–199 mg/dL define impaired glucose tolerance (IGT/prediabetes). The OGTT is the gold standard for diagnosing gestational diabetes and is sometimes used in early T2DM detection in at-risk populations.

• Hemoglobin A1C (HbA1C): HbA1C ≥6.5% (≥48 mmol/mol) is diagnostic of diabetes. HbA1C reflects average plasma glucose over the preceding 2–3 months (the lifespan of red blood cells) and is not influenced by acute fluctuations, food intake, or exercise on the day of testing. Values 5.7–6.4% (39–46 mmol/mol) define prediabetes. HbA1C is recommended for both diagnosis and monitoring of glycemic control.

Immediate stabilization (if the stem is acute)

• Hyperosmolar hyperglycemic state (HHS): profound osmotic diuresis with markedly elevated glucose, high effective osmolality, and minimal ketosis. Treat with aggressive isotonic IV fluids first, then IV regular insulin infusion, with potassium repletion begun before insulin if serum K is low — insulin drives K intracellularly and can precipitate lethal hypokalemia.

First-line therapy (ADA Standards of Care in Diabetes)

• Lifestyle modification: medical nutrition therapy, ≥150 min/week of moderate activity, and weight loss of at least 5–10%; resistance and aerobic exercise recruit GLUT4 via AMPK independent of insulin signaling.
• Biguanide — metformin: activates hepatic AMPK, suppresses gluconeogenesis, and does not cause hypoglycemia or weight gain. Remains first-line pharmacotherapy for most patients without compelling comorbidity.
• Comorbidity-driven agents: the ADA now recommends starting a GLP-1 receptor agonist (e.g., semaglutide, dulaglutide) or SGLT2 inhibitor (e.g., empagliflozin) independent of A1C or metformin use when established ASCVD, heart failure, or CKD is present. SGLT2 inhibitors are preferred with HFrEF/HFpEF or albuminuric CKD (also endorsed by KDIGO); GLP-1 RAs are preferred when atherosclerotic risk reduction and weight loss dominate.

Escalation

• Add a second agent by comorbidity, weight, hypoglycemia risk, and cost: DPP-4 inhibitor (sitagliptin), sulfonylurea (glipizide), thiazolidinedione (pioglitazone).
• Insulin: start basal insulin (glargine, detemir) when A1C remains above target on oral therapy, and start insulin up front if A1C is very high, glucose is markedly elevated, or the patient is catabolic/symptomatic — the picture may be glucotoxicity that reverses.
• Adjunctive risk reduction: statin therapy for adults 40–75 with diabetes, ACE inhibitor or ARB for hypertension with albuminuria, BP target <130/80 mm Hg.

Definitive/surgical

• Metabolic (bariatric) surgery: sleeve gastrectomy or Roux-en-Y gastric bypass produces durable remission, partly incretin-mediated; ADA endorses it in appropriate candidates with obesity, with lower BMI thresholds for Asian Americans.

Contraindications

• Metformin: avoid at eGFR <30 mL/min/1.73 m² (lactic acidosis); hold around iodinated contrast in impaired renal function.
• Thiazolidinediones: contraindicated in symptomatic heart failure (fluid retention).
• GLP-1 RAs: avoid with personal/family history of medullary thyroid carcinoma or MEN2.
• SGLT2 inhibitors: hold perioperatively — risk of euglycemic DKA.

Acute — emergencies

• Hyperosmolar hyperglycemic state (HHS): residual insulin suppresses ketogenesis but not hepatic glucose output; extreme hyperglycemia drives osmotic diuresis and free-water loss. Signaled by markedly elevated glucose, high effective serum osmolality, minimal/absent ketones, and altered mental status. Mortality exceeds that of DKA. Emergency.
• Diabetic ketoacidosis: less common in T2DM but occurs with severe stress or in ketosis-prone phenotypes. Euglycemic DKA is the classic SGLT2 inhibitor complication — anion-gap acidosis with ketones despite near-normal glucose, so a normal glucose must not reassure. Emergency.
• Hypoglycemia: the treatment complication of insulin and sulfonylureas (which close K_ATP channels regardless of glucose level). Adrenergic then neuroglycopenic symptoms; blunted awareness with autonomic neuropathy. Emergency.
• Rhinocerebral mucormycosis (black eschar on palate/turbinates) and malignant otitis externa (Pseudomonas, granulation tissue in the ear canal): impaired neutrophil function and acidosis. Emergencies.
• Fournier gangrene: necrotizing perineal fasciitis reported with SGLT2 inhibitors. Emergency.

Microvascular (AGE formation, polyol flux, protein kinase C activation)

• Retinopathy: microaneurysms, dot-blot hemorrhages, hard exudates → neovascularization. ADA advises dilated eye exam at diagnosis in T2DM.
• Nephropathy: hyperfiltration → Kimmelstiel–Wilson nodular glomerulosclerosis; signaled by rising urine albumin-to-creatinine ratio, screened annually with UACR and eGFR.
• Neuropathy: stocking-glove sensory loss, painless foot ulcers, Charcot arthropathy, gastroparesis, orthostasis.

Macrovascular

• Accelerated atherosclerosis: MI (often silent due to autonomic denervation), stroke, peripheral arterial disease with claudication and limb loss.

Drug-specific

• Metformin: lactic acidosis in renal failure/hypoxic states; chronic use causes vitamin B12 deficiency with macrocytic anemia and neuropathy that mimics diabetic neuropathy.
• Thiazolidinediones: edema, heart failure exacerbation, fractures.
• SGLT2 inhibitors: genital mycotic infections, volume depletion.
• GLP-1 RAs: nausea, delayed gastric emptying, pancreatitis.

• Comorbidity trumps A1C in drug choice: per the ADA Standards of Care, a patient with T2DM plus ASCVD, heart failure, or albuminuric CKD gets a GLP-1 receptor agonist or SGLT2 inhibitor regardless of A1C or metformin use. The stem that mentions heart failure or a rising UACR is testing this, not metformin titration.
• Metformin's stop point is renal: contraindicated at eGFR <30 mL/min/1.73 m². The common distractor is stopping it for elevated liver enzymes or for a normal-range creatinine.
• Euglycemic DKA: acidotic, ketotic patient on an SGLT2 inhibitor with a glucose that looks fine. Check an anion gap and beta-hydroxybutyrate — a normal glucose does not exclude DKA.
• HHS vs DKA: HHS = extreme hyperglycemia, high effective osmolality, minimal ketones, obtunded. Best next step is IV isotonic fluids, not an immediate insulin bolus; and give potassium before insulin if K is low-normal.
• Metformin and B12: new paresthesias plus macrocytic anemia in a long-term metformin user is B12 deficiency, not diabetic neuropathy (which does not cause macrocytosis).
• Screening timing: dilated retinal exam at diagnosis in T2DM (hyperglycemia predated diagnosis by years) versus 5 years after diagnosis in T1DM — a favorite discriminator.
• The classic association: Kimmelstiel–Wilson nodular glomerulosclerosis on biopsy is pathognomonic for diabetic nephropathy; the earliest clinical marker is moderately increased albuminuria on UACR, and the intervention is an ACE inhibitor or ARB (plus an SGLT2 inhibitor per KDIGO).
• Distractors to avoid: sulfonylureas cause hypoglycemia and weight gain and are not preferred in the elderly; thiazolidinediones are contraindicated in symptomatic heart failure; and ACE inhibitors — including captopril — are contraindicated in pregnancy, where insulin (and metformin in selected cases) is used instead.